In this Pain News Network column, CUSP’s chairman urges the U.S. Senate to pass S. 3257, a federal bill to remove an unnecessary barrier to medication for opioid use disorder. The bill would amend the Controlled Substances Act to increase the time providers can hold and administer long-acting, injectable buprenorphine from 14 days to 60 days. 

In June, the House of Representatives passed H.R. 7666 with broad bipartisan support. Section 264 of H.R. 7666 contains a provision expanding the 14-day limit to 60 days.

Read the full article at Pain News Network.